Usefulness of FDG PET for Assessment of Early Recurrent Epithelial Ovarian Cancer
- 1 August 2002
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 179 (2) , 391-395
- https://doi.org/10.2214/ajr.179.2.1790391
Abstract
OBJECTIVE. The purpose of our study was to evaluate the diagnostic accuracy of FDG positron emission tomography (PET) in comparison with CT in detecting recurrent ovarian carcinoma and its ability to reveal small tumor recurrence. MATERIALS AND METHODS. We reviewed the records of 31 consecutive patients with pathologically proven epithelial carcinoma who underwent FDG PET 1 month before second-look surgery to assess recurrent tumor. Of these 31 patients, 21 patients also underwent CT 1 month before second-look surgery. The diagnostic accuracies of FDG PET (n = 31), CT (n = 21), and combined FDG PET and CT (n = 21) in detecting recurrent tumor were calculated and compared with each other using the Bennett's test in 21 patients who underwent both imaging studies. Detection rates of individual tumors relative to their sizes were compared between FDG PET and CT using the McNemar test. RESULTS. The sensitivity, specificity, and accuracy of FDG PET, CT, and combined FDG PET and CT for revealing recurrent ovarian cancer were 45.3%, 99.7%, 91.0%; 54.5%, 99.6%, 91.7%; 58.2%, 99.6%, 92.4%, respectively. We found no statistically significant difference in the diagnostic accuracy of FDG PET, CT, and combined FDG PET and CT (χ2 < 5.991). Detection rates of tumor nodules found on CT were significantly greater than those on FDG PET when nodule size was 0.3-0.7 cm (p < 0.05). CONCLUSION. FDG PET did not improve the overall diagnostic accuracy in detecting recurrent ovarian carcinoma compared with CT. Rather, FDG PET was inferior to CT in its ability to reveal small-tumor recurrence.Keywords
This publication has 30 references indexed in Scilit:
- Clinical Value of Positron Emission Tomography with FDG for Recurrent Ovarian CancerAmerican Journal of Roentgenology, 2001
- Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinomaEuropean Radiology, 2000
- Whole-Body PET with (Fluorine-18)-2-deoxyglucose for Detecting Recurrent Primary Serous Peritoneal Carcinoma: An Initial ReportGynecologic Oncology, 2000
- The Prognostic Significance of Peritoneal Seeding and Size of Postsurgical Residual in Patients with Stage III Epithelial Ovarian Cancer Treated with Surgery, Chemotherapy, and High-Dose RadiotherapyGynecologic Oncology, 1999
- The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancerInternational Journal of Gynecologic Cancer, 1999
- Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1997
- Effect of Nicotine on Proliferation of Normal, Malignant, and Human Papillomavirus-Transformed Human Cervical CellsGynecologic Oncology, 1994
- Experience with Positron Emission Tomography (PET) Scans in Patients with Ovarian CancerGynecologic Oncology, 1994
- Whole-Body Positron Emission Tomography with 2-[18F]-Fluoro-2-deoxy-D-glucose Can Detect Recurrent Ovarian CarcinomaGynecologic Oncology, 1993
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993